Company profile: Tune Therapeutics
1.1 - Company Overview
Company description
- Provider of an epigenetic programming platform for disease treatment, offering TEMPO to control gene activity without altering DNA sequence by activating, silencing, or fine-tuning gene output, and TUNE-401, an investigational HBV therapy that epigenetically silences viral DNA in host chromosomes and cccDNA to pursue a functional cure.
Products and services
- Epigenetic Programming Platform: A custom-engineered platform for the treatment of disease by programming epigenetic states
- TEMPO: A programmable genetic tuning platform that controls gene activity without altering the DNA sequence, enabling disease treatment by activating, silencing, or fine-tuning gene output
- TUNE-401: An investigational epigenetic therapy targeting Hepatitis B by silencing viral DNA in host chromosomes and cccDNA, aiming for a functional cure.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tune Therapeutics
Stage Cell Therapeutics
HQ: Germany
Website
- Description: Provider of a proprietary Streptamer platform enabling rapid development and production of safe and efficient cell therapeutics; privately held biotech active since 2005.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stage Cell Therapeutics company profile →
Cergentis
HQ: The Netherlands
Website
- Description: Provider of services and kits based on proprietary Targeted Locus Amplification (TLA) technology, enabling cost-effective complete sequencing of relevant genes and genomic loci and providing genetic characterization and quality control (QC) to support the development of advanced, safe and effective therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cergentis company profile →
GreenLight Biosciences
HQ: United States
Website
- Description: Provider of RNA-based solutions for agriculture and human health, offering a proprietary platform to produce RNA at scale cost-effectively and products targeting pests and diseases without harming beneficial insects, including Varroa mite control for honeybees and Calantha, an EPA-approved RNA product for Colorado Potato Beetle control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GreenLight Biosciences company profile →
DropWorks
HQ: United States
Website
- Description: Provider of instrumentation and analytical techniques using novel continuous flow droplet nanoreactors, focused on digital PCR that delivers absolute nucleic acid quantification and ultra-high sensitivity through a simple, high-throughput, low-cost workflow, enabling multiplexed analysis without standard NB curves or pipeline replicates pipelines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DropWorks company profile →
Tome Biosciences
HQ: United States
Website
- Description: Provider of programmable gene insertion technologies, including Integrase-Mediated PGI using a proprietary integrase to integrate large DNA sequences (>1,000 bp) at user-defined genomic locations and Ligase-Mediated PGI using a DNA ligase for small sequence insertion, plus integrative gene therapies for PKU (PAH), ASCVD (ApoA-1), HCU (CBS), and hereditary hemochromatosis (HFE).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tome Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tune Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tune Therapeutics
2.2 - Growth funds investing in similar companies to Tune Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tune Therapeutics
4.2 - Public trading comparable groups for Tune Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →